Molecular Analysis-Based Treatment Prospects and Innovations for Diffuse Large B-Cell Lymphomas

This study explores the treatment prospects and innovations in diffuse large B-cell lymphoma (DLBCL) based on molecular analysis. We analyzed 110 patients diagnosed with DLBCL, conducting immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) to classify molecular subtypes and identify key genetic mutations. Our research focused on assessing the efficacy of traditional R-CHOP therapy compared to novel targeted treatments, including CAR-T cell therapy, bispecific antibodies, and BTK inhibitors. The results showed that molecular profiling significantly impacts treatment outcomes, with high-risk genetic subtypes responding better to personalized therapies. Double-hit and triple-hit lymphomas demonstrated poor response to standard therapy but improved survival with CAR-T treatment. Targeted drugs such as EZH2 inhibitors and immune checkpoint inhibitors also showed promising results in refractory cases. This study highlights the importance of molecular diagnostics in guiding treatment strategies and emphasizes the need for further research to optimize individualized therapy for DLBCL patients.